Phase 2 N=115 S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants
Phase 2 N=87 A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Neoplasms
Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) — 1; 1; 1; 5 Participants
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Phase 2 N=66 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Phase 2 N=50 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Acute Leukemia of Ambiguous Lineage · Acute Myeloid Leukemia · Myeloid Neoplasm
Primary: Feasibility Defined as Proportion of Patients Willing to be Randomized to Either Intensive or Non-intensive Induction and Post Remission Chemotherapy — 3; 47 Participants
Phase 2 N=204 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Acute Myelogenous Leukemia · Lymphoid Leukemia · Chronic Myelogenous Leukemia
Primary: Median Disease-free Survival — 333 Days
N/A N=30 Exercise Prehab in Older Adults With Hematologic Malignancies
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Phase 2 N=63 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Erythroid Leukemia · Acute Megakaryoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLT) — 2; 1; 0; 0 Participants
Phase 2 N=40 Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Leukemia, Erythroblastic, Acute · Myelodysplastic Syndromes
Primary: Disease Free Survival at 1 Year Post-transplant — 18 Participants
Phase 1 N=51 APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Myeloid Malignancy
Primary: To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in…
Phase 2 N=24 Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Myeloid Malignancies · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced Graft Failure — 0 Participants
Phase 2 N=109 Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
Chronic Myeloid Leukemia · Blast Crisis
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants
Phase 2 N=38 Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants